2018
Radiofrekvenční ablace endometria – nová možnost konzervativní léčby silného menstruačního krvácení
HUSER, Martin, Z. PAPIKOVA, M. DZIAKOVA, Robert HUDEČEK, Pavel VENTRUBA et. al.Základní údaje
Originální název
Radiofrekvenční ablace endometria – nová možnost konzervativní léčby silného menstruačního krvácení
Název anglicky
Radiofrequency endometrial ablation - new possibility of heavy menstrual bleeding conservative treatment
Autoři
HUSER, Martin (203 Česká republika, garant, domácí), Z. PAPIKOVA (203 Česká republika), M. DZIAKOVA (203 Česká republika), Robert HUDEČEK (203 Česká republika, domácí) a Pavel VENTRUBA (203 Česká republika, domácí)
Vydání
ČESKÁ GYNEKOLOGIE-CZECH GYNAECOLOGY, PRAGUE, NAKLADATELSKE STREDISKO C L S J E PURKYNE, 2018, 1210-7832
Další údaje
Jazyk
čeština
Typ výsledku
Článek v odborném periodiku
Obor
30214 Obstetrics and gynaecology
Stát vydavatele
Česká republika
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Kód RIV
RIV/00216224:14110/18:00110181
Organizační jednotka
Lékařská fakulta
UT WoS
000470771500001
Klíčová slova anglicky
heavy menstrual bleeding; hysteroscopy; radiofrequency endometrial ablation; amenorrhoea; complications
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 11. 5. 2020 09:33, Mgr. Tereza Miškechová
V originále
Cíl studie: Vyhodnocení efektivity ablace endometria technikou radiofrekvenční ablace (RFAE) u pacientek se silným menstruačním krvácením (SMK).
Anglicky
Objective: Evaluation of radiofrequency endometrial ablation (RFEA) clinical efficacy in patients with heavy menstrual bleeding (HMB). Design: Original article. Setting: Department of Gynecology and Obstetrics, University Hospital and Masaryk University Medical School, Brno. Methods: Study included 20 patients with HMB who had failed hormonal therapy and met the study inclusion criteria. All RFEA procedures were performed in the operating theater in general anesthesia by two experienced surgeons according to a standardized protocol. All RFEA were performed using specific disposable electrodes and radio frequency generator M-3004 (RF Medical Co.. South Korea). Study outcomes were evaluated three months post-surgery included percentage of women with amenorrhoea or menstrual bleeding persistence measured by the modified Pictorial Blood Assessment Chart (PBAC) score. Furthermore, chronic pelvic pain intensity assessed by visual analogue scale (VAS), patient satisfaction (Patient Global Impression of Improvement, PGI-I score), and the incidence of complications were evaluated. Results: All RFEAs were performed without operational or technical complications. the average age being operated was 43.0 +/- 2.9 years and the operating time did not exceed ten minutes. In the early postoperative follow-up, patients did not require any analgesics and were all released to outpatient care the following day. Percentage of amenorrhea at three months post-treatment was 35.0%. mean PBAC score for women with menstrual bleeding was 1.8 +/- 0.6. Patient's satisfaction with the treatment was evaluated by 1.6 +/- 0.6 on the PGI-I scale and long-term pelvic pain was on average 2.1 +/- 0.8 by VAS, which counts an improvement of 31.0%. Conclusion: The HMB treatment with RFEA achieves good clinical results in three-month evaluation with objective and also subjective parameters. The technique is suitable for outpatient treatment and is an alternative to hysteroscopy endometrial ablation. Its wider clinical usage is limited by the high cost of the radiofrequency generator and disposable probes.